Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
News|Articles|November 4, 2025
5 Nephrology Headlines You Missed in October 2025
Author(s)Alex Hillenbrand
Fact checked by: Abigail Brooks, MA
October brings FDA approvals, new KDIGO guidance, and diagnostic breakthroughs
Advertisement
Advertisement
October delivered a slew of significant developments in nephrology, underscoring rapid momentum in both therapeutic innovation and clinical guidance. The month was highlighted by a landmark US Food and Drug Administration (FDA) approval in lupus nephritis for obinutuzumab, accompanied by new phase 3 data in IgA nephropathy (IgAN), reinforcing continued progress toward more effective, individualized treatment.
Related to this article
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Advertisement
Advertisement